top of page
Science
BT_darkbg_closedface.png

Engineered to

redefine toxins

Recombinant Botulinum Neurotoxin

A scalable recombinant botulinum toxin production platform enabling rapid and safe engineering through recombinant expression.

Recombinant BoNT(rBoNT)

Conventional botulinum toxin(BoNT) products have faced inherent limitations due to their reliance on naturally occurring strains of Clostridium botulinum strains for production. MVRIX overcomes these constraints by producing botulium toxin using E. coli as  a host strain, unlocking the full and virtually unlimited potential of botulinum  Toxin.

Conventional BoNT

Difficulty securing strains with desired properties

Classfied High-risk biological agent, requiring strict safety control

Limited flexibility for structural and functional modification

Conventional botulinum toxin products are produced only from naturally occurring strains of Clostridium botulinum. However, such strains are extremely rare in nature, and securing diverse types suitable for pharmaceutical use remains an even greater challenge.

Recombinant BoNT

Flexible strain origin, easier IP protection

Safe and rapid production process

Engineering-driven performance enhancement

Recombinant botulinum neurotoxins ensure high safety through an E. coli–based production process and enable diverse performance enhancements through precise engineering.

튜브 라이트

Advantages

Core toxins resistant to immunity

Core toxins can be produced quickly and safely without inducing resistance.

Improved botulinum toxins

Botulinum toxins can be developed with faster onset and longer duration of action.

Domain engineering

By engineering different domains of botulinum toxins, their indications can be expanded.

Improved 

Production system

  • We use E. coli as the host to eliminate the risk of strain disputes and to produce core toxins with a very low likelihood of resistance.

  • The recombinant production process  improves safety and maximizes efficiency by shortening production timelines.

ecoli copy.jpg

Overexpression

Broader Application

Various serotypes can be produced in E. coli, and with our engineering techniques, they can be adapted to a wide range of indications, from aesthetic use to medical applications.

Botulinum toxin consists of three core domains: LC, Hn, and Hc.

R&D Achievements

Discover the intellectual property activities we are pursuing around rBoNT.

bottom of page